查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1888723

基因检测市场规模、份额和趋势分析报告：按疾病类型、技术、地区和细分市场预测（2025-2033 年）

Hereditary Testing Market Size, Share & Trends Analysis Report By Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing), By Technology (Cytogenetic, Biochemical, Molecular Testing), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 270 Pages | 商品交期: 2-10个工作天内

价格

基因检测市场摘要

2024 年全球基因检测市场规模估计为 161.6 亿美元，预计到 2033 年将达到 526.6 亿美元，2025 年至 2033 年的复合年增长率为 14.42%，这主要受遗传疾病和相关慢性疾病日益普遍的推动。

随着越来越多的患者被诊断出患有遗传性癌症、心血管疾病、METABOLIC INC.症候群和罕见的基因异常，对早期准确检测的需求正在急剧上升。

由于许多遗传疾病通常在成年后才出现，因此早期检测对于预防、后续观察和医疗决策至关重要。此外，新生儿和婴儿筛检的加强也发现了许多以前未被发现的遗传异常。随着临床意识的提高，医生越来越频繁地将基因检测纳入常规风险评估。此外，随着人口老化，某些癌症和神经退化性疾病等与老龄化相关的遗传疾病日益增多，促使人们进行更深入的基因评估。这些因素共同凸显了基因检测在症状出现前识别健康风险的重要作用，从而推动了市场的持续成长。

目录

第一章 基因检测市场：调查方法与范围

2. 基因检测市场：执行摘要

  • 市场概览
  • 按疾病类型分類的技术概述
  • 竞争格局概述

3. 基因检测市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关及附随市场展望
  • 市场动态
  • 市场驱动因素分析
    • DNA检测套组的销售量与需求增加
    • 女性生殖健康商业格局的持续演变
    • 定序成本下降以及由此导致的基因检测登记库的扩张
  • 市场限制因素分析
    • DNA检测相关的伦理和临床问题
    • DTC基因检测应用面临的监管挑战
  • 市场机会分析
    • 遗传性疾病发生率增加
    • 人们对早期、非侵入性的胎儿检测程序有需求。
    • 在基因组学价值链中实施零散的点式解决方案
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第四章 基因检测市场：依疾病类型分類的估算与趋势分析

  • 基因检测市场：依疾病类型分類的差异分析
  • 遗传性癌症检测
    • 乳癌
    • 肺癌
    • 大肠直肠癌
    • 子宫颈癌
    • 卵巢癌
    • 摄护腺癌
    • 胃癌
    • 恶性黑色素瘤
    • 肉瘤
    • 子宫癌
    • 胰臟癌
    • 其他的
  • 遗传性非癌症检测
    • 基因检测
    • 胚胎着床前遗传学诊断与筛检
    • 非侵入性产前检测 (NIPT) 和携带者筛检测试
    • 新生儿基因筛检

第五章 基因检测市场：依技术分類的估算与趋势分析

  • 基因检测市场：技术变革分析
  • 细胞遗传学
  • 生物化学
  • 分子检测

第六章 基因检测市场：区域业务分析

  • 区域市场概览
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第七章 竞争情势

  • 公司分类
  • 策略规划
    • 新产品发布
    • 合伙
    • 获得
    • 合资
    • 资金筹措
  • 主要企业市占率分析（2024 年）
  • 公司热力图分析
  • 公司简介
    • Myriad Genetics, Inc.
    • Invitae Corporation
    • Illumina, Inc.
    • Natera, Inc.
    • Laboratory Corporation of America Holdings
    • F. Hoffmann-La Roche Ltd.
    • Quest Diagnostics Incorporated
    • COOPERSURGICAL, INC.
    • Agilent Technologies, Inc.
    • Thermo Fisher Scientific, Inc.
    • Twist Bioscience
    • SOPHiA GENETICS
    • Fulgent Genetics
    • MedGenome
    • CENTOGENE NV
Product Code: GVR-4-68038-999-9

Hereditary Testing Market Summary

The global hereditary testing market size was estimated at USD 16.16 billion in 2024 and is projected to reach USD 52.66 billion by 2033, growing at a CAGR of 14.42% from 2025 to 2033, due to the increasing prevalence of genetic disorders and related chronic conditions. As more individuals are diagnosed with inherited cancers, cardiovascular diseases, metabolic syndromes, and rare genetic abnormalities, the demand for early and accurate detection has surged.

Many hereditary conditions often manifest later in life, making early testing essential for prevention, monitoring, and medical decision-making. Moreover, increased screening of newborns and infants has highlighted a substantial number of genetic abnormalities that previously went undetected. With better clinical awareness, physicians are recommending genetic testing more often as part of routine risk assessment. In addition, as populations age, age-related hereditary conditions-such as certain cancers and neurodegenerative disorders-are becoming more common, encouraging more genetic evaluations. Together, these factors drive sustained market growth by emphasizing the critical role of hereditary testing in identifying health risks before symptoms emerge.

Global Hereditary Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global hereditary testing market report on the basis of disease type, technology, and region.

  • Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Hereditary Cancer Testing
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Stomach/Gastric Cancer
    • Melanoma
    • Sarcoma
    • Uterine Cancer
    • Pancreatic Cancer
    • Others
  • Hereditary Non-cancer Testing
    • Genetic Tests
    • Cardiac Diseases
    • Rare Diseases
    • Other Diseases
    • Preimplantation Genetic Diagnosis & Screening
    • Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
    • Newborn Genetic Screening
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Cytogenetic
  • Biochemical
  • Molecular Testing
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait

Table of Contents

Chapter 1. Hereditary Testing Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Disease Type
      • 1.1.1.2. Technology Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Hereditary Testing Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Disease Type Technology Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Hereditary Testing Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increase in sales and demand for DNA test kits
    • 3.4.2. Constantly developing commercial landscape of women's reproductive health
    • 3.4.3. Decline in sequencing cost & consequent expansion of genetic testing registry
  • 3.5. Market Restraint Analysis
    • 3.5.1. Ethical and clinical issues of DNA tests
    • 3.5.2. Regulatory challenges pertaining to use of DTC genetic tests
  • 3.6. Market Opportunity Analysis
    • 3.6.1. Increasing incidence of genetic diseases
    • 3.6.2. Presence of demand for early and non-invasive fetal testing procedures
    • 3.6.3. Introduction of fragmented point-solutions across the genomics value chain
  • 3.7. Porter's Five Forces Analysis
  • 3.8. PESTLE Analysis
  • 3.9. Pipeline Analysis

Chapter 4. Hereditary Testing Market: Disease Type Estimates & Trend Analysis

  • 4.1. Hereditary Testing Market: Disease Type Movement Analysis
  • 4.2. Hereditary Cancer Testing
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2. Breast Cancer
      • 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.3. Lung Cancer
      • 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.4. Colorectal Cancer
      • 4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.5. Cervical Cancer
      • 4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.6. Ovarian Cancer
      • 4.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.7. Prostate Cancer
      • 4.2.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.8. Stomach/Gastric Cancer
      • 4.2.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.9. Melanoma
      • 4.2.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.10. Sarcoma
      • 4.2.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.11. Uterine Cancer
      • 4.2.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.12. Pancreatic Cancer
      • 4.2.12.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.13. Others
      • 4.2.13.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Hereditary Non-cancer Testing
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2. Genetic Tests
      • 4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.2. Cardiac Diseases
        • 4.3.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.3. Rare Diseases
        • 4.3.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.4. Other Diseases
        • 4.3.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3. Preimplantation Genetic Diagnosis & Screening
      • 4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.4. Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
      • 4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.5. Newborn Genetic Screening
      • 4.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Hereditary Testing Market: Technology Estimates & Trend Analysis

  • 5.1. Hereditary Testing Market: Technology Movement Analysis
  • 5.2. Cytogenetic
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Biochemical
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Molecular Testing
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Hereditary Testing Market: Regional Business Analysis

  • 6.1. Regional Market Snapshot
  • 6.2. North America
    • 6.2.1. North America Hereditary Testing Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.2.2.2. Key Country Dynamics
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. Reimbursement Scenario
      • 6.2.2.5. Competitive Scenario
    • 6.2.3. Canada
      • 6.2.3.1. Canada Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.2.3.2. Key Country Dynamics
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Reimbursement Scenario
      • 6.2.3.5. Competitive Scenario
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.2.4.2. Key Country Dynamics
      • 6.2.4.3. Regulatory Framework
      • 6.2.4.4. Reimbursement Scenario
      • 6.2.4.5. Competitive Scenario
  • 6.3. Europe
    • 6.3.1. Europe Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.3.2.2. Key Country Dynamics
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Reimbursement Scenario
      • 6.3.2.5. Competitive Scenario
    • 6.3.3. Germany
      • 6.3.3.1. Germany Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.3.3.2. Key Country Dynamics
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Reimbursement Scenario
      • 6.3.3.5. Competitive Scenario
    • 6.3.4. Spain
      • 6.3.4.1. Spain Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.3.4.2. Key Country Dynamics
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Reimbursement Scenario
      • 6.3.4.5. Competitive Scenario
    • 6.3.5. France
      • 6.3.5.1. France Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.3.5.2. Key Country Dynamics
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Reimbursement Scenario
      • 6.3.5.5. Competitive Scenario
    • 6.3.6. Italy
      • 6.3.6.1. Italy Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.3.6.2. Key Country Dynamics
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Reimbursement Scenario
      • 6.3.6.5. Competitive Scenario
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.3.7.2. Key Country Dynamics
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Reimbursement Scenario
      • 6.3.7.5. Competitive Scenario
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.3.8.2. Key Country Dynamics
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Reimbursement Scenario
      • 6.3.8.5. Competitive Scenario
    • 6.3.9. Norway
      • 6.3.9.1. Norway Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.3.9.2. Key Country Dynamics
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Reimbursement Scenario
      • 6.3.9.5. Competitive Scenario
  • 6.4. Asia Pacific
    • 6.4.1. Asia-Pacific Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.4.2.2. Key Country Dynamics
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Scenario
      • 6.4.2.5. Competitive Scenario
    • 6.4.3. China
      • 6.4.3.1. China Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.4.3.2. Key Country Dynamics
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Scenario
      • 6.4.3.5. Competitive Scenario
    • 6.4.4. India
      • 6.4.4.1. India Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.4.4.2. Key Country Dynamics
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Scenario
      • 6.4.4.5. Competitive Scenario
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.4.5.2. Key Country Dynamics
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Reimbursement Scenario
      • 6.4.5.5. Competitive Scenario
    • 6.4.6. Thailand
      • 6.4.6.1. Thailand Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.4.6.2. Key Country Dynamics
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Reimbursement Scenario
      • 6.4.6.5. Competitive Scenario
    • 6.4.7. Australia
      • 6.4.7.1. Australia Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.4.7.2. Key Country Dynamics
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Reimbursement Scenario
      • 6.4.7.5. Competitive Scenario
  • 6.5. Latin America
    • 6.5.1. Latin America Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.5.2.2. Key Country Dynamics
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Scenario
      • 6.5.2.5. Competitive Scenario
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.5.3.2. Key Country Dynamics
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Scenario
      • 6.5.3.5. Competitive Scenario
  • 6.6. Middle East & Africa
    • 6.6.1. Middle East & Africa Hereditary Testing Market, 2021 - 2033 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.6.2.2. Key Country Dynamics
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Scenario
      • 6.6.2.5. Competitive Scenario
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.6.3.2. Key Country Dynamics
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Scenario
      • 6.6.3.5. Competitive Scenario
    • 6.6.4. UAE
      • 6.6.4.1. UAE Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.6.4.2. Key Country Dynamics
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Scenario
      • 6.6.4.5. Competitive Scenario
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Hereditary Testing Market, 2021 - 2033 (USD Million)
      • 6.6.5.2. Key Country Dynamics
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Scenario
      • 6.6.5.5. Competitive Scenario

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
    • 7.2.1. New Product Launch
    • 7.2.2. Partnerships
    • 7.2.3. Acquisition
    • 7.2.4. Collaboration
    • 7.2.5. Funding
  • 7.3. Key Company Market Share Analysis, 2024
  • 7.4. Company Heat Map Analysis
  • 7.5. Company Profiles
    • 7.5.1. Myriad Genetics, Inc.
      • 7.5.1.1. Company Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Invitae Corporation
      • 7.5.2.1. Company Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Illumina, Inc.
      • 7.5.3.1. Company Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Natera, Inc.
      • 7.5.4.1. Company Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Laboratory Corporation of America Holdings
      • 7.5.5.1. Company Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. F. Hoffmann-La Roche Ltd.
      • 7.5.6.1. Company Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Quest Diagnostics Incorporated
      • 7.5.7.1. Company Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. COOPERSURGICAL, INC.
      • 7.5.8.1. Company Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Agilent Technologies, Inc.
      • 7.5.9.1. Company Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Thermo Fisher Scientific, Inc.
      • 7.5.10.1. Company Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Twist Bioscience
      • 7.5.11.1. Company Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives
    • 7.5.12. SOPHiA GENETICS
      • 7.5.12.1. Company Overview
      • 7.5.12.2. Financial Performance
      • 7.5.12.3. Product Benchmarking
      • 7.5.12.4. Strategic Initiatives
    • 7.5.13. Fulgent Genetics
      • 7.5.13.1. Company Overview
      • 7.5.13.2. Financial Performance
      • 7.5.13.3. Product Benchmarking
      • 7.5.13.4. Strategic Initiatives
    • 7.5.14. MedGenome
      • 7.5.14.1. Company Overview
      • 7.5.14.2. Financial Performance
      • 7.5.14.3. Product Benchmarking
      • 7.5.14.4. Strategic Initiatives
    • 7.5.15. CENTOGENE N.V.
      • 7.5.15.1. Company Overview
      • 7.5.15.2. Financial Performance
      • 7.5.15.3. Product Benchmarking
      • 7.5.15.4. Strategic Initiatives

List of Tables

  • Table 1 Product mapping for hereditary cancer tests
  • Table 2 DNA sequencing costs over the past decade
  • Table 3 Global incidence rate of genetic disorders
  • Table 4 Technology landscape for NIPT tests
  • Table 5 Comparison of other technologies
  • Table 6 Countries that prescribe mandatory medical supervision & restriction for genetic tests
  • Table 7 Susceptibility genes and their prevalence in hereditary ovarian syndromes
  • Table 8 Various NGS tests for hereditary prostate cancer
  • Table 9 Genetic testing scenario for patients/families affected by inherited cardiac disease
  • Table 10 Financial solutions for PGT:
  • Table 11 Commercial landscape of NIPT for fetal aneuploidy in the U.S.
  • Table 12 North America hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 16 North America hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 17 U.S. hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 18 U.S. hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 19 Canada hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 20 Canada hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 21 Mexico hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 22 Mexico hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 23 Europe hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 35 Europe hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 36 UK hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 37 UK hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 38 Germany hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 39 Germany hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 40 France hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 41 France hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 42 Spain hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 43 Spain hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 43 Italy hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 44 Italy hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 45 Denmark hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 46 Denmark hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 47 Sweden hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 48 Sweden hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 49 Norway hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 50 Norway hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 52 Asia Pacific hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 53 China hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 54 China hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 55 Japan hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 56 Japan hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 57 India hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 58 India hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 59 South Korea hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 60 South Korea hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 61 Australia hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 62 Australia hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 63 Thailand hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 64 Thailand hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 65 Latin America hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 66 Latin America hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 67 Brazil hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 68 Brazil hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 69 Argentina hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 70 Argentina hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 71 Middle East & Africa hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 72 Middle East & Africa hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 73 South Africa hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 74 South Africa hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 75 Saudi Arabia hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 76 Saudi Arabia hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 77 UAE hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 79 UAE hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
  • Table 80 Kuwait hereditary testing market estimates & forecasts, by disease type, 2021 - 2033 (USD Million)
  • Table 81 Kuwait hereditary testing market estimates & forecasts, by technology, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Hereditary Testing Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration Vs Growth Prospect Mapping, 2024
  • Fig. 15 Regional Marketplace: Key Takeaways
  • Fig. 16 Regional Outlook, 2024 & 2033
  • Fig. 17 North America Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 18 U.S. Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 19 Mexico Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 19 Canada Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 20 Europe Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 21 Germany Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 22 UK Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 23 France Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 24 Spain Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 25 Italy Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 26 Denmark Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 27 Sweden Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 28 Norway Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 29 Asia Pacific Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 30 Japan Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 31 China Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 32 India Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 33 Australia Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 34 South Korea Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 35 Thailand Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 36 Latin America Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 37 Brazil Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 39 Argentina Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 40 Middle East and Africa Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 41 South Africa Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 42 Saudi Arabia Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 43 UAE Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 44 Kuwait Hereditary Testing Market, 2021 - 2033 (USD Million)
  • Fig. 45 Global Hereditary Testing Market, for, Hereditary Cancer Testing 2021 - 2033 (USD Million)
  • Fig. 46 Global Hereditary Testing Market, for, Lung Cancer 2021 - 2033 (USD Million)
  • Fig. 47 Global Hereditary Testing Market, for, Breast Cancer 2021 - 2033 (USD Million)
  • Fig. 48 Global Hereditary Testing Market, for, Colorectal Cancer 2021 - 2033 (USD Million)
  • Fig. 49 Global Hereditary Testing Market, for, Cervical Cancer 2021 - 2033 (USD Million)
  • Fig. 50 Global Hereditary Testing Market, for, Ovarian Cancer 2021 - 2033 (USD Million)
  • Fig. 51 Global Hereditary Testing Market, for, Prostate Cancer 2021 - 2033 (USD Million)
  • Fig. 52 Global Hereditary Testing Market, for, Stomach/Gastric Cancer 2021 - 2033 (USD Million)
  • Fig. 53 Global Hereditary Testing Market, for, Melanoma 2021 - 2033 (USD Million)
  • Fig. 54 Global Hereditary Testing Market, for, Sarcoma 2021 - 2033 (USD Million)
  • Fig. 55 Global Hereditary Testing Market, for, Uterine Cancer 2021 - 2033 (USD Million)
  • Fig. 56 Global Hereditary Testing Market, for, Pancreatic Cancer 2021 - 2033 (USD Million)
  • Fig. 57 Global Hereditary Testing Market, for, Others 2021 - 2033 (USD Million)
  • Fig. 58 Global Hereditary Testing Market, for, Genetic Tests 2021 - 2033 (USD Million)
  • Fig. 59 Global Hereditary Testing Market, for, Cardiac Diseases 2021 - 2033 (USD Million)
  • Fig. 60 Global Hereditary Testing Market, for, Rare Diseases 2021 - 2033 (USD Million)
  • Fig. 61 Global Hereditary Testing Market, for, Other Diseases 2021 - 2033 (USD Million)
  • Fig. 62 Global Hereditary Testing Market, for, Newborn Genetic Screening 2021 - 2033 (USD Million)
  • Fig. 63 Global Hereditary Testing Market, for, Preimplantation Genetic Diagnosis & Screening 2021 - 2033 (USD Million)
  • Fig. 64 Global Hereditary Testing Market, for, Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests 2021 - 2033 (USD Million)
  • Fig. 65 Global Hereditary Testing Market, for, Cytogenetic 2021 - 2033 (USD Million)
  • Fig. 66 Global Hereditary Testing Market, for, Biochemical 2021 - 2033 (USD Million)
  • Fig. 67 Global Hereditary Testing Market, for, Molecular Testing 2021 - 2033 (USD Million)